| INTRODUCTION
The burden of cardiovascular disease (CVD) in the United States is high, with 92.1 million adults (46.7 million aged at least 60 years) experiencing at least one cardiovascular event during 2011 to 2014; 7.9 million experienced myocardial infarction (MI) and 7.2 million experienced stroke. 1 In 2014, CVD accounted for 30.8% of all deaths. 1 In addition, CVD is the most costly chronic disease in the United States, with estimated direct costs projected to increase from 318 billion dollars in 2015 to 749 billion dollars by 2035. 2 The preponderance of this cost burden is projected to be attributable to patients at least 65 years of age (450 and 200 billion dollars for individuals ≥80 and 65 to 79 years old, respectively, by 2035). 2 Survivors of MI or stroke are at high risk for recurrence, other cardiovascular events, or death. For example, a recent analysis of the FOURIER trial demonstrated that high-risk patients with a history of CVD and maximally tolerated statin therapy are at substantial risk for the recurrence of multiple cardiovascular events. 3 Among survivors of first MI between 2004 and 2010 in England, recurrence rates were 5.6% for men and 7.2% for women at 1 year, and 13.9% and 16.2%, respectively, at 7 years. 4 Every year, approximately 795 000 people in the United States experience a stroke, 23 .3% of which are recurrent events. 1 Other studies of stroke recurrence have reported cumulative recurrence rates of 8.0% to 12.6% at 1 year, 10.8% to 12.1% at 2 years, and 16.6% at 5 years. [5] [6] [7] [8] Among patients surviving a stroke, the incidence of all-cause death was 24.5% at 1 year and 41.3% at 4 years. 5 Moreover, healthcare costs in Medicare beneficiaries who have a recurrent CVD event following an MI are 2-fold greater compared with the period prior to the initial event. 9 Older age and presence of diabetes are known risk factors for CVD. 1, 4, [10] [11] [12] CVD prevalence rates of 70% and 86% for patients aged 60 to 79 years and 80 years or older have been reported. Mortality rates, both all-cause and CVD-related, for patients with diabetes are approximately 2-fold higher than those for patients without diabetes, and increasing duration of diabetes is associated with increasing CVD risk. 13, 14 Although it is important to understand the burden of CVD in these high-risk populations, few studies have systematically examined the real-world pattern of recurrent cardiovascular events in older patients overall or by diabetes status. A recent systematic literature review found that the rates of secondary major adverse cardiovascular events among patients with atherosclerotic CVD were greater in realworld studies compared with randomized clinical trials; however, this study did not investigate the risk in elderly patients or patients with diabetes. 15 We estimated cumulative recurrence rates of MI and ischemic stroke (IS) after hospital discharge and cumulative incidence of other cardiovascular events, all-cause death, and composite measures of multiple events after MI or IS over long-term follow-up in a 2008 cohort of older patients. We also examined the association between diabetes status and 1-year risk of MI or IS recurrence and the incidence of other CVD outcomes in a 2012 cohort.
| METHODS
We analyzed a 20% random sample of Centers for Medicare & Medic- For each disease cohort in 2008, we estimated the cumulative incidence of outcome variables for the 6-year follow-up period using the Kaplan-Meier method. For each non-death outcome, we estimated the cumulative incidence function to treat death as a competing event.
To examine associations between diabetes status and rates of cardiovascular events and all-cause mortality in the 2012 MI and IS cohorts, we used the Fine and Gray model incorporating death as a competing risk event to estimate the relative risk (diabetes vs non-diabetes) for outcomes not including death as a component. 16 For outcomes including death as a component, we used Cox regression to estimate the relative risk (diabetes vs non-diabetes). All models were adjusted for age, sex, race, and baseline conditions, including prior In the 2012 MI cohort, 7.2% of the patients experienced a recurrent MI in the first year after the index MI, and the recurrence rate when accounting for multiple MI recurrences was 11.6 per 100 patient-years (Table 2 ). In 2012 IS cohort, the incidence of recurrent IS was 6.7% during the first year, and the event rate was 10. The cumulative incidence of cardiovascular events following an index event for the 2008 cohort is presented in Figure 1 (A, MI cohort; B, IS cohort). After an index MI event, the incidence of MI recurrence was 5.7% at 6 months, 7.7% at 1 year, 11.7% at 3 years, and 14.3% at 6 years. After an index IS event, the incidence of IS recurrence was 4.9% at 6 months, 6.7% at 1 year, 10.8% at 3 years, and 13.4% at 6 years. Among patients in the MI and IS cohorts with 1 year of follow-up, 9.5% and 8.5%, respectively, experienced the composite outcome of MI, IS, or UA (Table 3) . When the composite outcome also included CABG/PCI, rates were 16.9% for the MI cohort and 9.4% for the IS cohort. The cumulative incidence for the composite outcomes increased over time; after 6 years of follow-up, the cumulative incidence for the MI, IS, or UA composite outcome was 18.9% in the MI cohort and 18.0% in the IS cohort (27.5% and 19.9%, respectively, when CABG/PCI was included).
Patterns for the cumulative incidence of death after an index event were similar for the 2008 MI and IS cohorts ( Figure 1C ). After an index MI event, the cumulative incidence of death was 25.0% at 6 months, 32.3% at 1 year, 51.4% at 3 years, and 69.2% at 6 years.
After an index IS event, the cumulative incidence of death was 25.5% at 6 months, 32.7% at 1 year, 51.9% at 3 years, and 70.2% at 6 years. Figure 2A ). In the IS cohort, diabetes was significantly associated with higher IS recurrence (ARR, 1.26; 95% CI, 1.12-1.42; Figure 2B ). Diabetes was not significantly associated with all-cause death in either disease cohort. Risks for composite measures that included MI, IS, or UA and MI, IS, UA, or CABG/PCI were significantly higher for patients with diabetes in both the MI and IS cohorts; however, composite measures that included death were significant only in the MI cohort. The number and percentage of patients with at least one CVD event following the index event is presented by diabetes status in Table S2 .
| DISCUSSION
The results of the present analysis indicate that the first year following an event of MI or IS represents a critical period for potential secondary prevention in older patients with CVD. We observed a high rate 
FIGURE 2 Adjusted risk ratios of outcomes associated with diabetes: 2012 (A) MI and (B) IS cohorts. CABG, coronary artery bypass grafting; IS, ischemic stroke; LCI, lower confidence interval; MI, myocardial infarction; PCI, percutaneous coronary intervention; RR, risk ratio; UA, unstable angina; UCI, upper confidence interval of MI and IS recurrence in the first year of survival after an MI or IS (7.7% and 6.7%, respectively), and the risk of recurrence persisted and continued to increase for up to 6 years of follow-up (14.3% and 13.4%, respectively). These findings confirm results from other retrospective observational studies, in which the risk of recurrent events was highest in the first year but remained elevated in subsequent years. 17, 18 Moreover, many patients in this Medicare sample experi- sure were multiple recurrent events. 3 Patients in FOURIER were younger and were receiving moderate-or high-intensity statin therapy; thus, higher multiple recurrence rates might be expected among older patients in real-world clinical practice.
The prevalence of comorbidities such as hypertension and diabetes, was high in the study population, and as shown in other studies, diabetes is a significant risk factor for recurrent events. [17] [18] [19] [20] [21] In the Hoorn cohort study, the incidence of a recurrent cardiovascular event during approximately 4 years of follow-up was 60% higher for individuals with diabetes compared with those without, and higher glycated hemoglobin was one of the predictive risk factors for a recurrent event. 21 A recent systematic review of morbidity and mortality in patients who survived for at least 1 year following MI found that older age, history of stroke, and comorbidities, including diabetes, hypertension, peripheral artery disease, and renal disease, were associated with a greater risk of recurrent cardiovascular events or death. 20 Overall, these findings highlight the need for clinicians to closely monitor and aggressively treat these high-risk patients after discharge for MI or IS to ensure that relevant prognostic factors such as lipid, glucose, and blood pressure levels are achieved according to guidelines. [22] [23] [24] [25] [26] This study has some important limitations. First, it was an observational study using a 20% Medicare random sample; therefore, the sever- 
